HomeNationCovaxin safe, well-tolerated in 2-18 years age-group: Bharat Biotech

Covaxin safe, well-tolerated in 2-18 years age-group: Bharat Biotech

@the_news_21

Bharat Biotech International Limited (BBIL) on Friday announced that its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects in phase II/III study.

A press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer reviewed high impact factor journal.

Bharat Biotech had conducted phase II/III, open-label, and multi-centre study to evaluate the safety, reactogenicity and immunogenicity of Covaxin in healthy children and adolescents in 2-18 years age group.

The clinical trial conducted in the paediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity. The data was submitted to the Central Drugs Standard Control Organisation (CDSCO) during October 2021, and received a nod for emergency use in children aged 6-18 years.

Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “Safety of the vaccine is critical for children and we are glad to share that Covaxin has now proven data for safety and immunogenicity in children. We have now achieved our goal of developing a safe and efficacious COVID-19 vaccine for adults and children, for primary immunisation and booster doses, making Covaxin a universal vaccine.”

It has proven to be a highly safe vaccine based on data from more than 50 million doses administered to children in India. Vaccines are a great preventive tool and the power of vaccines can only be harnessed if used “prophylactically,” he further said.

In the study, no serious adverse event was reported. A total of 374 adverse events were reported, and the majority of adverse events were mild in nature and resolved within one day. Pain at the injection site was the most commonly reported adverse event, the release said.

Subscribe to TheNews21

Stay Ahead with Independent Journalism

Investigations, political analysis and major national and global stories delivered directly to your inbox.

Stay Ahead with Independent Journalism

Investigations, political analysis and major national and global stories delivered directly to your inbox.

40 COMMENTS

  1. Join stake mines today and experience the ultimate crypto casino vibe. Instant deposits, massive withdrawals, and provably fair games — everything a real player deserves. The original crypto gambling legend is waiting for you. Jump in now!

  2. Join the millions enchanting colossal on fanduel casino Texas – the #1 legitimate coins casino app in America.
    Pick up your $1000 OPERATE IT AGAIN honorarium and turn every spin, hand and somersault into real readies rewards.
    Fast payouts, immense jackpots, and day in effect – download FanDuel Casino in these times and start playing like a pro today!

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Must Read

spot_img

@the_news_21

Bharat Biotech International Limited (BBIL) on Friday announced that its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects in phase II/III study.

A press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer reviewed high impact factor journal.

Bharat Biotech had conducted phase II/III, open-label, and multi-centre study to evaluate the safety, reactogenicity and immunogenicity of Covaxin in healthy children and adolescents in 2-18 years age group.

The clinical trial conducted in the paediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity. The data was submitted to the Central Drugs Standard Control Organisation (CDSCO) during October 2021, and received a nod for emergency use in children aged 6-18 years.

Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “Safety of the vaccine is critical for children and we are glad to share that Covaxin has now proven data for safety and immunogenicity in children. We have now achieved our goal of developing a safe and efficacious COVID-19 vaccine for adults and children, for primary immunisation and booster doses, making Covaxin a universal vaccine.”

It has proven to be a highly safe vaccine based on data from more than 50 million doses administered to children in India. Vaccines are a great preventive tool and the power of vaccines can only be harnessed if used “prophylactically,” he further said.

In the study, no serious adverse event was reported. A total of 374 adverse events were reported, and the majority of adverse events were mild in nature and resolved within one day. Pain at the injection site was the most commonly reported adverse event, the release said.

Html code here! Replace this with any non empty text and that's it.

40 COMMENTS

  1. Join stake mines today and experience the ultimate crypto casino vibe. Instant deposits, massive withdrawals, and provably fair games — everything a real player deserves. The original crypto gambling legend is waiting for you. Jump in now!

  2. Join the millions enchanting colossal on fanduel casino Texas – the #1 legitimate coins casino app in America.
    Pick up your $1000 OPERATE IT AGAIN honorarium and turn every spin, hand and somersault into real readies rewards.
    Fast payouts, immense jackpots, and day in effect – download FanDuel Casino in these times and start playing like a pro today!

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Must Read

spot_img